Foghorn Therapeutics
FHTX
61 hedge funds and large institutions have $135M invested in Foghorn Therapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 15 increasing their positions, 20 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
3% more funds holding
Funds holding: 59 → 61 (+2)
0.34% more ownership
Funds ownership: 63.98% → 64.32% (+0.34%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
25% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 20
29% less capital invested
Capital invested by funds: $188M → $135M (-$53.8M)
Top Buyers
Top Sellers
FHTX Hedge Fund Activity: Q3 2023 in Review
61 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q3 2023, worth a combined $135M — down 29% from $188M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new FHTX positions and 1 closed out — a net gain of 2 holders — while 15 added to existing stakes and 20 trimmed.
The largest buyer was Raymond James & Associates, adding an estimated $1.81M. The largest seller was BlackRock, cutting an estimated $491K.
- 61 institutional investors held Foghorn Therapeutics (FHTX) as of Q3 2023, up from 59 in Q2 2023.
- Funds reported $135M of Foghorn Therapeutics stock for Q3 2023, down 29% quarter-over-quarter.
- 3 funds opened new Foghorn Therapeutics positions in Q3 2023 and 1 closed out, a net change of +2 holders.
- The largest Foghorn Therapeutics buyer in Q3 2023 was Raymond James & Associates, an estimated $1.81M added.
- The largest Foghorn Therapeutics seller in Q3 2023 was BlackRock, an estimated $491K sold.
Based on aggregated 13F filings for Q3 2023.